FEDERAL COURT OF AUSTRALIA
Cancer Voices Australia v Myriad Genetics Inc [2013] FCA 65
Citation: Cancer Voices Australia v Myriad Genetics Inc [2013] FCA 65 Parties: CANCER VOICES AUSTRALIA and YVONNE D'ARCY v MYRIAD GENETICS INC and GENETIC TECHNOLOGIES LIMITED (ABN 17 009 212 328) File number: NSD 643 of 2010 Judge: NICHOLAS J Date of judgment: 15 February 2013 Corrigendum: 25 February 2013 Catchwords: PATENTS – Patent including claims for isolated DNA and RNA (nucleic acid) – whether claims to composition comprising naturally occurring DNA and RNA that has been isolated are for a manner of manufacture for purposes of s 18(1)(a) of Patents Act 1990 (Cth) – where isolated DNA and RNA has been extracted from cells removed from human body and purged of other biological material with which it is associated in the cell – whether isolation of naturally occurring DNA and RNA results in an artificial state of affairs with a discernible effect – whether claims to isolated DNA and RNA are to a “mere discovery” and therefore not patentable – whether claims to isolated DNA and RNA are to a “product of nature” and therefore not patentable – whether order revoking challenged claims should be made
Held: each of challenged claims is to a manner of manufacture – requirements of s 18(1)(a) of Patents Act 1990 (Cth) satisfied – where non-compliance with requirements of s 18(1)(a) sole ground relied upon in support of application for orders revoking challenged claims – application dismissed with costs.
Legislation: Patents Act 1990 (Cth) s 18
Statute of Monopolies s 6
Patents Act 1949 (UK)
Patents Bill 1990 (Cth)
Patent Amendment (Human Genes and Biological Materials) Bill 2010 (Cth)
Intellectual Property Laws Amendment (Raising the Bar) Act 2012 (Cth)Cases cited: Advanced Building Systems Pty Limited v Ramset Fasteners (Aust) Pty Limited (1998) 194 CLR 171
American Cyanamid Company v Upjohn Company [1971] RPC 425
CCOM Pty Ltd v Jiejing Pty Ltd (1994) 51 FCR 260
Diamond v Chakrabarty 447 US 303
Festo Corp. v Shoketsu Kinzoku Kogyu Kabushiki Co. 535 US 722, 739 (2002)
Funk Bros. Seed Co. v Kalo Inoculant Co. (1948) 333 US 127
Genentech Inc’s Patent [1987] RPC 553
Grain Pool of Western Australia v Commonwealth of Australia (2000) 202 CLR 479
Joos v Commissioner of Patents (1972) 126 CLR 611
Kirin-Amgen Inc v Board of Regents of University of Washington (1995) 33 IPR 557
Kirin-Amgen Inc v Hoechst Marion Roussel Ltd [2005] RPC 169
Mayo Collaborative Services v Prometheus Laboratories Inc 132 SCt 1289 (2012)
National Research Development Corporation v Commissioner of Patents (1959) 102 CLR 252
Re GEC’s Application (1943) 60 RPC 1
Reynolds v Herbert Smith & Co Ltd (1903) 20 RPC 123
The Association for Molecular Pathology & Ors v United States Patent and Trademark Officeand Myriad Genetics Inc 653 F3d 1329 (2011)
The Association for Molecular Pathology & Ors v United States Patent and Trademark Officeand Myriad Genetics Inc 689 F3d 1303 (2012)Andrew Stewart, Phillip Griffith and…
Keep reading for free
Create a free CaseChat account to read Cancer Voices Australia v Myriad Genetics Inc and more:
- Read every judgment in full
- Ask AI and get answers linked to paragraphs
- See how each paragraph was cited in later cases
- Download judgments as PDF or Word
One click creates your free account or signs you in.
By continuing you agree to the Terms and Privacy Policy.
- Case
- [2013] FCA 65
- Decision Date
CaseChat Overview and Summary
The court found that the isolated nucleic acids were patentable subject matter under section 18(1)(a) of the Act. The court held that the isolation of naturally occurring DNA and RNA resulted in an artificial state of affairs with a discernible effect, and that the claims to isolated nucleic acids were to a manner of manufacture and not to a mere discovery or product of nature. The court also noted that the Act does not specifically preclude the grant of a patent for isolated DNA or RNA sequences, and that it was not the intention of Parliament to deal with the issue of "gene patenting" by way of express statutory exclusion. The court further held that the subject matter of the disputed claims satisfied the second essential quality of an invention, which is "economic significance".
The court dismissed the application to revoke the challenged claims with costs. The applicants were given 21 days to file a notice of appeal, after which the costs order would become effective. The court's decision provides guidance on the patentability of isolated nucleic acids in Australia and clarifies the scope of section 18(1)(a) of the Act.
Orders
Orders of the court
1. The amended application be dismissed.
2. The applicants pay the respondents’ costs.
3. Subject to any further order, order 2 is stayed for 21 days and, if a notice of appeal is filed within that time, until the determination of the appeal.
Note: Entry of orders is dealt with in Rule 39.32 of the Federal Court Rules 2011
Background
Background to the litigation
Evidence
Evidence Before The Court
Decision
Reasons for decision
Ratio Decidendi
Legal Principle Established
Section 18(1A) of the Act is concerned with innovation patents. It is not necessary to set s 18(1A) out. As with standard patents, the invention the subject of a claim in an innovation patent must be a manner of manufacture. Section 18(1A) is followed by s 18(2)-(4). They provide:(2)Human beings, and the biological processes for their generation, are not patentable inventions.(3)For the purposes of an innovation patent, plants and animals, and the biological processes for the generation of plants and animals, are not patentable inventions.(4)Subsection (3) does not apply if the invention is a microbiological process or a product of such a process.National Research Development Corporation v Commissioner of Patents The starting point for my consideration of the legal issues that arise is the High Court’s decision in the NRDC case. The case was described by Barwick CJ in Joos v Commissioner of Patents (1972) 126 CLR 611 at 616 as a “watershed” in this area of law, and in Grain Pool of Western Australia v Commonwealth of Australia (2000) 202 CLR 479 at para [45] Gleeson CJ, Gaudron, McHugh, Gummow, Hayne and Callinan JJ referred to it as a “celebrated judgment”. As the Full Court (Spender, Gummow and Heerey JJ) explained in CCOM Pty Ltd v Jiejing Pty Ltd (1994) 51 FCR 260 (at 289): In Australia, when the 1952 Act was replaced by the 1990 Act, the new British legislation was not followed. There was in s 18(2) an express exclusion from patentable inventions of human beings and biological processes for their generation. Beyond that the legislature left the matter, in terms of s 18(1)(a), to rest with the concept of manner of manufacture within the meaning of s 6 of the Statute of Monopolies, as developed by the Courts, notably in the NRDC case. This was a matter of deliberate legislative choice. There were three claims in issue in the NRDC case. All were method claims concerned with the use of a known chemical composition (“herbicide”) in the eradication or control of weeds. The first claim was directed to the use of the herbicide in the eradication of weeds from areas containing leguminous fodder crops of the Trifolium and Medicago families, as well as celery and parsnip. The second and third claims were directed to the use of the herbicide to control charlock, creeping thistle and annual nettle weeds in different crop varieties. The examiner raised objections to these claims on the basis that none was directed to any manner of manufacture. There were two arguments relied upon by the examiner in support of that conclusion. The first was that the claims involved “the mere use of known substances” and the second was that the use of these substances did “not result in any vendible product”. Both arguments relied upon by the examiner were also relied upon by the Commissioner of Patents (the Commissioner) in the High Court. The first was rejected by the High Court on the basis that the invention as claimed involved a new and inventive use of a known chemical composition. The second was also rejected by the High Court.